Immunotherapy for Lung Cancer: Success Rates, Types, and Prospects

Understand how immunotherapy is revolutionizing the fight against lung cancer, including its types, effectiveness, and side effects.

By Medha deb

Created on Sep 26, 2025

Understand how immunotherapy is revolutionizing the fight against lung cancer, including its types, effectiveness, and side effects.

Immunotherapy for Lung Cancer: An In-Depth Guide

Lung cancer remains one of the most diagnosed and deadly cancers worldwide, affecting millions of people each year. Advances in treatment have improved outcomes for many patients, and immunotherapy now plays a central role in managing lung cancer, especially when traditional treatments like chemotherapy and surgery are not effective or no longer viable.
This guide explores how immunotherapy works for lung cancer, success rates, types of treatment, side effects, clinical trial data, and the outlook for the future.

How Does Immunotherapy Work for Lung Cancer?

Immunotherapy harnesses the body’s natural immune system to recognize and attack lung cancer cells. While the immune system is adept at targeting threats like bacteria and viruses, cancer cells can sometimes evade detection by mimicking healthy tissues or hiding from immune defenses.
Immunotherapy agents work by enhancing or redirecting immune responses so that cancer cells are more easily recognized and destroyed.

Immune checkpoint inhibitors: Block the molecules (such as PD-1, PD-L1, and CTLA-4) that tumors use to suppress immune attacks, unleashing T-cells to seek out and destroy cancer cells.
Monoclonal antibodies: Laboratory-made proteins that can bind specifically to cancer cell markers or help the immune system recognize and destroy these cells.
Tumor vaccines: Stimulate the immune system to attack specific antigens unique to tumor cells.

Types of Immunotherapy Used for Lung Cancer

There are several main types of immunotherapy currently used or being studied for lung cancer treatment:

Immune Checkpoint Inhibitors: Block pathways that cancer cells use to evade the immune system. Common drugs in this category include pembrolizumab, nivolumab, atezolizumab, durvalumab, and ipilimumab.
Monoclonal Antibodies: Designed to target specific cancer cell antigens or stimulate immune activity (e.g., bevacizumab, cetuximab).
Cancer Vaccines: Experimental vaccines aimed at stimulating immunity specifically against lung cancer cells.
Adoptive Cell Therapy: Modifying a patient’s own T cells in the laboratory to enhance their ability to fight cancer (still largely experimental for lung cancer).

Who Are Candidates for Immunotherapy?

Immunotherapy is most commonly used for people with non-small cell lung cancer (NSCLC), which makes up approximately 85-90% of lung cancers, especially when the cancer is advanced or recurrent. It can be given:

As a first-line treatment in advanced NSCLC, often in combination with chemotherapy
As second-line therapy when previous treatments fail
Sometimes as consolidation therapy following chemoradiation in unresectable, locally advanced disease
Less frequently as adjuvant therapy following surgery

Immunotherapy is also approved for extensive-stage small cell lung cancer (SCLC) in combination with chemotherapy, though benefits are generally more limited compared to NSCLC.

Success Rates of Immunotherapy for Lung Cancer

Immunotherapy has helped improve the survival rates for certain lung cancer patients, particularly those with advanced or inoperable disease. However, response varies greatly between individuals, cancer types, and treatment combinations.

Treatment	Patient Group	Median Overall Survival Increase	Key Insight
Atezolizumab + Chemotherapy	Extensive-stage SCLC	~2 months	Modest survival benefit over chemotherapy alone
Durvalumab + Chemotherapy	Extensive-stage SCLC	Significant OS improvement	Better outcomes vs. standard chemotherapy
Checkpoint Inhibitor Monotherapy	NSCLC	Highly variable	Best results in patients with high PD-L1 expression
Combination Immunotherapy (e.g., Ipilimumab + Nivolumab)	Some advanced lung cancers	Improved progression-free survival	Enhanced response in specific subgroups

The exact success rate depends on many factors including cancer type (NSCLC vs SCLC), stage of disease, molecular characteristics of the tumor (such as PD-L1 expression), overall health, and combination with other treatments.
Some key findings from recent clinical trials include:

Immunotherapy can extend life expectancy by several months compared to chemotherapy alone in some settings.
Effects appear more pronounced in people whose tumors express higher levels of specific markers (like PD-L1).
Combination with chemotherapy often yields better results than immunotherapy alone.
Most patients do not experience a complete response; partial responses and slowed progression are more common.

Side Effects of Immunotherapy

Like all treatments, immunotherapy comes with potential side effects. These can range from mild to severe and may appear shortly after starting treatment or much later:

Fatigue
Skin reactions (rashes, itching, vitiligo)
Digestive issues (nausea, diarrhea, colitis)
Lung problems (such as pneumonitis, which may cause cough and shortness of breath)
Endocrine changes (thyroiditis, changes in hormone levels)
Fever, joint pain, muscle aches

Most side effects are manageable but can sometimes be severe enough to require pausing or stopping treatment. Prompt reporting of symptoms to your care team is essential for managing adverse effects early.

Who Should Avoid Immunotherapy?

Immunotherapy is not suitable for everyone. People with specific health conditions may be unable to tolerate treatment or may have higher risks for serious adverse events. These factors include:

Pre-existing autoimmune diseases (e.g., lupus, multiple sclerosis, rheumatoid arthritis)
Organ transplant recipients (risk of organ rejection)
Certain chronic infections (e.g., active hepatitis or tuberculosis)
Severe allergies to biological medications
Poor overall health or organ function

Immunotherapy in Combination with Other Treatments

Immunotherapy is often used alongside other traditional therapies for lung cancer:

Chemotherapy: Combined regimens may improve effectiveness, especially in extensive-stage SCLC.
Radiation therapy: Sometimes given before, simultaneously, or after immunotherapy to shrink tumors and enhance response.
Surgery: Less common, but immunotherapy may be used before (neoadjuvant) or after (adjuvant) surgical resection in selected cases.

Participation in Clinical Trials

Because the field of immunotherapy is rapidly evolving, many new drugs and combinations are being tested in clinical trials. Enrolling in a clinical trial can provide access to promising new therapies and help advance research in this field. Speak with your oncology team about ongoing or upcoming trials that may be right for you.

Future Outlook for Immunotherapy in Lung Cancer

Immunotherapy is transforming the outlook for many lung cancer patients, particularly those with advanced or hard-to-treat disease. Although it does not work for everyone, and benefits can be modest or variable, ongoing research is focused on:

Identifying biomarkers to predict who will respond best (e.g., PD-L1, tumor mutation burden)
Refining combination therapies for enhanced effectiveness
Developing next-generation immunotherapeutics (cancer vaccines, engineered immune cells, new checkpoints)
Understanding and overcoming resistance to treatment

While challenges remain—such as delayed side effects, treatment resistance, and incomplete response—immunotherapy continues to provide hope for extending survival and improving quality of life in lung cancer patients.

Frequently Asked Questions (FAQs)

Q: How long can you live on immunotherapy for lung cancer?

A: The length of survival varies. Some patients live for months to years longer than expected with standard therapy, especially if they respond well to treatment. Individual prognosis depends on many factors, including cancer type, stage, and biomarker status.

Q: Is immunotherapy a cure for lung cancer?

A: In most cases, immunotherapy is not a cure but can prolong life and slow disease progression. A small minority of patients may experience long-lasting remission.

Q: What are the signs that immunotherapy is working?

A: Doctors monitor for tumor shrinkage on imaging scans, slowed progression, or stable disease. Improved symptoms and fewer signs of disease-related decline can also indicate benefit.

Q: Are there alternatives if immunotherapy doesn’t work?

A: Yes, options may include different immunotherapy agents, targeted therapies (for specific genetic mutations), chemotherapy, radiation, and enrollment in clinical trials offering experimental treatments.

Q: Can side effects from immunotherapy be managed?

A: Many side effects can be managed with prompt medical attention, supportive treatments, or temporary breaks from immunotherapy. Severe reactions may require steroids or discontinuation of treatment.

References

Author

medha deb

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb